Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
Clinical trial NCT02799602 · COMPLETED
Trial details
- NCT number
- NCT02799602
- Sponsor
- Bayer
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-11-30
- Primary completion
- 2021-10-25
- Enrollment
- 1306
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.